|
Re: I think I'm going to have to schedule another call.....
|
5
|
Resverlogix Corp.
|
Dec 04, 2017 04:34PM
|
|
Re: Zenith
|
5
|
Resverlogix Corp.
|
May 13, 2015 01:38PM
|
|
Re: What would a success NR look like?
|
5
|
Resverlogix Corp.
|
Mar 30, 2019 04:27PM
|
|
Cardiovascular organ damage in T2DM: the role of lipids and inflammation
|
5
|
Resverlogix Corp.
|
May 11, 2019 08:20AM
|
|
Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the ASCO Conference
|
5
|
Zenith Epigenetics
|
Jun 21, 2022 08:03AM
|
|
Re: No show at Rodman and Renshaw?
|
5
|
Resverlogix Corp.
|
Sep 12, 2017 10:10AM
|
|
Re: Since GAC....
|
5
|
Resverlogix Corp.
|
Feb 28, 2020 11:17PM
|
|
BET inhibitors induce senolysis
|
5
|
Zenith Epigenetics
|
Apr 23, 2020 07:54AM
|
|
RVX AGM Q&A, post AGM-huddle, impressions
|
5
|
Resverlogix Corp.
|
Sep 18, 2018 08:29PM
|
|
Renal Phase 2a Trial Now Listed on ClinicalTrial.gov
|
5
|
Resverlogix Corp.
|
May 19, 2017 01:06PM
|
|
Re: European Atherosclerosis Society Congress May 29 - June 1
|
5
|
Resverlogix Corp.
|
May 26, 2016 01:36PM
|
|
Re: Anacetrapib Officially Bites the Dust
|
5
|
Resverlogix Corp.
|
Oct 26, 2017 03:22PM
|
|
Hong Kong stock exchange IPO
|
5
|
Resverlogix Corp.
|
Apr 25, 2018 08:50AM
|
|
Re: Avoid The Bag - Blog post preview....
|
5
|
Resverlogix Corp.
|
Mar 30, 2017 03:28PM
|
|
NYAS Epigenetics: Cancer and Beyond Symposium eBriefing
|
5
|
Resverlogix Corp.
|
Jul 07, 2016 07:28PM
|
|
Zacks SCR Report 12/20/2017
|
4
|
Resverlogix Corp.
|
Dec 23, 2017 08:43AM
|
|
Re: Patent Applications in U.S. and Europe
|
4
|
BIOASIS TECHNOLOGIES INC
|
Jun 25, 2019 06:55AM
|
|
Re: Article Mentioning Apabetalone
|
4
|
Resverlogix Corp.
|
Jun 22, 2018 10:58AM
|
|
Re: An email and response from another poster.
|
4
|
Resverlogix Corp.
|
Dec 04, 2018 09:34PM
|
|
Re: Roth Conference March 19th 11:00 AM Fireside Chat
|
4
|
Resverlogix Corp.
|
Mar 15, 2019 02:12PM
|
